Med'Inn'Pharma

Med'Inn'Pharma is a French biotechnology company dedicated to developing a new generation of human cell-derived therapeutics that leverage the body's natural resolution of inflammation. Spun off from the French National Institute of Health (INSERM) and the French Blood Bank (EFS), the company utilizes its proprietary APO-Drug platform to produce secretomes—complex mixtures of bioactive molecules—derived from human apoptotic cells. These secretome-based candidates, such as MRT and Resolvix, are designed to re-educate the immune system and promote tissue healing rather than simply suppressing immune responses. The company's lead program for rheumatoid arthritis is advancing toward clinical evaluation, while its candidate for systemic sclerosis addresses a critical unmet need in rare fibrotic diseases. Med'Inn'Pharma's approach aims to provide safer, durable alternatives to standard corticosteroids and immunosuppressants for chronic inflammatory and degenerative conditions.